Patient Satisfaction in Chamber Setting in Bangladesh measured by Patient-Doctor Relationship Questionnaire (PDRQ-9 Bangla)

Background: Assessment of patient satisfaction is crucial but there is significant lagging in this sector. Patient satisfaction is an important indicator of health care quality as well as a predictor of treatment adherence. The Good patient-doctor relationship is considered as an integral part of the patient satisfaction. In Bangladesh, this domain is yet to be explored in a large scale. Aim: It was aimed to look into the patient satisfaction level in chamber setting in Bangladesh measured using the patient-doctor relationship questionnaire (PDRQ-9 Bangla). Methods: PDRQ-9 is a short yet excellent tool for assessing the patient-doctor relationship. The data collection was done in private chamber setting by the PDRQ-9 and analyzed. Results: Though the result was not completely in line with the existing literature, the PDRQ-9 was found to be a useful and brief measurement tool in the context of the patient-doctor relationship. Conclusion: Large-scale research in this particular aspect of patient satisfaction in future may provide a more succinct resul

Herbal treatment of secretory diarrhea

The research study is conducted to understand interaction of illness, symptoms, context, patients response and the clinical skill vis a vis better management of secretory diarrhea. Specific aim of this study is to determine the impact of intensive medical intervention with herbal drug “Dirasif” (Test) and allopathic drug “Furoxone” (Control) to treat secretory diarrhea. This is randomized controlled clinical trial in primary care with an open intervention. All patients judged by the physician to need either herbal or allopathic medicine for secretory diarrhea are randomized in treatment therapy. Clinical trial was conducted on hundred patients from both groups i.e.50 patient from control and 50 from experimental group having age between 12-40 year.Comparison of data recorded by participants relating to these variables showed significant differences between test and control groups (p < 0.05) despite the fact that no side effects were recorded in test group. Overall clinical success was observed in both treatment groups however the efficacy of the test treated medication (Dirasif) was superior as p=0.03. Dirasif is more effective than the Furoxone in the treatment of secretory diarrhea in Gadap community Karachi, Pakistan.Keywords: Secretory diarrhea, efficacy, dirasif, furoxon

Herbal treatment of secretory diarrhea

The research study is conducted to understand interaction of illness, symptoms, context, patients response and the clinical skill vis a vis better management of secretory diarrhea. Specific aim of this study is to determine the impact of intensive medical intervention with herbal drug “Dirasif” (Test) and allopathic drug “Furoxone” (Control) to treat secretory diarrhea. This is randomized controlled clinical trial in primary care with an open intervention. All patients judged by the physician to need either herbal or allopathic medicine for secretory diarrhea are randomized in treatment therapy. Clinical trial was conducted on hundred patients from both groups i.e.50 patient from control and 50 from experimental group having age between 12-40 year.Comparison of data recorded by participants relating to these variables showed significant differences between test and control groups (p < 0.05) despite the fact that no side effects were recorded in test group. Overall clinical success was observed in both treatment groups however the efficacy of the test treated medication (Dirasif) was superior as p=0.03. Dirasif is more effective than the Furoxone in the treatment of secretory diarrhea in Gadap community Karachi, Pakistan.Keywords: Secretory diarrhea, efficacy, dirasif, furoxon

Monograph of Holarrhena antidysenterica (linn.) Wall

Holarrhena Antidysenterica is a very significant herbal drug in Unani system of medicine and Ayurvedic system of medicine. This meticulous herb was used to treat a variety of infectious diseases especially in Staphylococcus aureus, Entamoeba histolytica and Escherichia coli. It is a large tree of 30 to 40 feet in height grows widely on the mountains. A large number of pharmacological studies have been done on the bark and seed of the tree.Keywords: Holarrhena Antidysenterica, Conessine, amoebic dysenter

Synthesis and in silico study of 2-furyl(4-{4-[(substituted)sulfonyl]benzyl}-1-piperazinyl)methanone derivatives as suitable therapeutic agents

Abstract In the study presented here, a new series of 2-furyl(4-{4-[(substituted)sulfonyl]benzyl}-1-piperazinyl)methanone derivatives was targeted. The synthesis was initiated by the treatment of different secondary amines (1a-h) with 4-bromomethylbenzenesulfonyl chloride (2) to obtain various 1-{[4-(bromomethyl)phenyl]sulfonyl}amines (3a-h). 2-Furyl(1-piperazinyl)methanone (2-furoyl-1-piperazine; 4) was then dissolved in acetonitrile, with the addition of K2CO3, and the mixture was refluxed for activation. This activated molecule was further treated with equi-molar amounts of 3a-h to form targeted 2-furyl(4-{4-[(substituted)sulfonyl]benzyl}-1-piperazinyl)methanone derivatives (5a-h) in the same reaction set up. The structure confirmation of all the synthesized compounds was carried out by EI-MS, IR and 1H-NMR spectral analysis. The compounds showed good enzyme inhibitory activity. Compound 5h showed excellent inhibitory effect against acetyl- and butyrylcholinesterase with respective IC50 values of 2.91±0.001 and 4.35±0.004 μM, compared to eserine, a reference standard with IC50 values of 0.04±0.0001 and 0.85±0.001 μM, respectively, against these enzymes. All synthesized molecules were active against almost all Gram-positive and Gram-negative bacterial strains tested. The cytotoxicity of the molecules was also checked to determine their utility as possible therapeutic agents

Ward Identities, B-> \rho Form Factors and |V_ub|

The exclusive FCNC beauty semileptonic decay B-> \rho is studied using Ward identities in a general vector meson dominance framework, predicting vector meson couplings involved. The long distance contributions are discussed which results to obtain form factors and |V_ub|. A detailed comparison is given with other approaches.Comment: 30 pages+four postscript figures, an Appendix adde

Observation of hard scattering in photoproduction events with a large rapidity gap at HERA

Events with a large rapidity gap and total transverse energy greater than 5 GeV have been observed in quasi-real photoproduction at HERA with the ZEUS detector. The distribution of these events as a function of the $\gamma p$ centre of mass energy is consistent with diffractive scattering. For total transverse energies above 12 GeV, the hadronic final states show predominantly a two-jet structure with each jet having a transverse energy greater than 4 GeV. For the two-jet events, little energy flow is found outside the jets. This observation is consistent with the hard scattering of a quasi-real photon with a colourless object in the proton.Comment: 19 pages, latex, 4 figures appended as uuencoded fil

D* Production in Deep Inelastic Scattering at HERA

This paper presents measurements of D^{*\pm} production in deep inelastic scattering from collisions between 27.5 GeV positrons and 820 GeV protons. The data have been taken with the ZEUS detector at HERA. The decay channel $D^{*+}\to (D^0 \to K^- \pi^+) \pi^+$ (+ c.c.) has been used in the study. The $e^+p$ cross section for inclusive D^{*\pm} production with $5<Q^2<100 GeV^2$ and $y<0.7$ is 5.3 \pms 1.0 \pms 0.8 nb in the kinematic region {$1.3<p_T(D^{*\pm})<9.0$ GeV and $| \eta(D^{*\pm}) |<1.5$}. Differential cross sections as functions of p_T(D^{*\pm}), $\eta(D^{*\pm}), W$ and $Q^2$ are compared with next-to-leading order QCD calculations based on the photon-gluon fusion production mechanism. After an extrapolation of the cross section to the full kinematic region in p_T(D^{*\pm}) and $\eta$(D^{*\pm}), the charm contribution $F_2^{c\bar{c}}(x,Q^2)$ to the proton structure function is determined for Bjorken $x$ between 2 $\cdot$ 10$^{-4}$ and 5 $\cdot$ 10$^{-3}$.Comment: 17 pages including 4 figure

Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia:a Multinational Point Prevalence Study of Hospitalised Patients

Pseudornonas aeruginosa is a challenging bacterium to treat due to its intrinsic resistance to the antibiotics used most frequently in patients with community-acquired pneumonia (CAP). Data about the global burden and risk factors associated with P. aeruginosa-CAP are limited. We assessed the multinational burden and specific risk factors associated with P. aeruginosa-CAP. We enrolled 3193 patients in 54 countries with confirmed diagnosis of CAP who underwent microbiological testing at admission. Prevalence was calculated according to the identification of P. aeruginosa. Logistic regression analysis was used to identify risk factors for antibiotic-susceptible and antibiotic-resistant P. aeruginosa-CAP. The prevalence of P. aeruginosa and antibiotic-resistant P. aeruginosa-CAP was 4.2% and 2.0%, respectively. The rate of P. aeruginosa CAP in patients with prior infection/colonisation due to P. aeruginosa and at least one of the three independently associated chronic lung diseases (i.e. tracheostomy, bronchiectasis and/or very severe chronic obstructive pulmonary disease) was 67%. In contrast, the rate of P. aeruginosa-CAP was 2% in patients without prior P. aeruginosa infection/colonisation and none of the selected chronic lung diseases. The multinational prevalence of P. aeruginosa-CAP is low. The risk factors identified in this study may guide healthcare professionals in deciding empirical antibiotic coverage for CAP patients

Geographical and temporal distribution of SARS-CoV-2 clades in the WHO European Region, January to June 2020

We show the distribution of SARS-CoV-2 genetic clades over time and between countries and outline potential genomic surveillance objectives. We applied three available genomic nomenclature systems for SARS-CoV-2 to all sequence data from the WHO European Region available during the COVID-19 pandemic until 10 July 2020. We highlight the importance of real-time sequencing and data dissemination in a pandemic situation. We provide a comparison of the nomenclatures and lay a foundation for future European genomic surveillance of SARS-CoV-2.Peer reviewe